Greenwich LifeSciences, Inc. (GLSI) vs Inhibikase Therapeutics, Inc. (IKT)
A side-by-side comparison of Greenwich LifeSciences, Inc. and Inhibikase Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GLSI
Greenwich LifeSciences, Inc.
$16.51HealthcareDelayed quote: Oct 6, 2026, 12:23 PM EDT
IKT
Inhibikase Therapeutics, Inc.
$2.02HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — GLSI vs IKT
growth of $100 · dividends reinvested · last 6yGLSI -57.8% (-13.4%/yr)IKT -96.6% (-43.2%/yr)GLSI compounded faster over this window
Log scale — wide-divergence pair
GLSI IKT
GLSI vs IKT: by the numbers
- •IKT is the larger company ($266M vs $242M market cap).
Metrics side by side
Valuation
| Metric | GLSI | IKT |
|---|---|---|
| P/B ratio | 77.75 | 1.74 |
Profitability
| Metric | GLSI | IKT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -695.56% | -39.55% |
| ROIC | -701.55% | -42.92% |
Growth (annualized)
| Metric | GLSI | IKT |
|---|---|---|
| Total return CAGR (5Y) | -14.84% | -29.10% |
Frequently asked
- How have GLSI and IKT total returns compared?
- Over the past 5 years, GLSI delivered -14.84% and IKT delivered -29.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.